On August 31, 2026, AEON Biopharma, Inc. disclosed plans to attend Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference in New York City on September 10, 2026. AEON, trading on NYSE American as AEON, is a biopharmaceutical company working on ABP-450 as a biosimilar to BOTOX for therapeutic purposes in order to secure full-label U.S. market approval. The announcement stated that AEON's management will be conducting face-to-face 1x1 meetings with investors during the conference.